A Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 36 patients (estimated)
- Sponsors
- Icahn School of Medicine at Mount Sinai
- Tags
- ARK5 Inhibitor, Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor), CDK4
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1863
- NCT Identifier
- NCT06351644
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.